Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H11ClO3 |
Molecular Weight | 226.656 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1
InChI
InChIKey=ARHWPKZXBHOEEE-UHFFFAOYSA-N
InChI=1S/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)
Molecular Formula | C11H11ClO3 |
Molecular Weight | 226.656 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/21068Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26888
https://www.gov.uk/drug-safety-update/aceclofenac-preservex-updated-cardiovascular-advice-in-line-with-diclofenac-and-cox-2-inhibitors
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21068
Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26888
https://www.gov.uk/drug-safety-update/aceclofenac-preservex-updated-cardiovascular-advice-in-line-with-diclofenac-and-cox-2-inhibitors
Alclofenac (Preservex) is a non-steroidal anti-inflammatory agent advocated for use in rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis. Aceclofenac has little pharmacological activity itself; its main mode of action is through its metabolites which include diclofenac and 4’-hydroxy diclofenac. Skin rash is the most frequent side-effect, which in a small proportion of affected patients may be associated with systemic effects. A cutaneous reaction appears to be more likely in patients with a history of previous allergy to penicillin and other drugs. In June 2013 was told about the new contraindications and warnings for diclofenac. This was after a review by European regulators concluded that the risk of arterial thrombotic events (myocardial infarction; stroke) with diclofenac is greater than with other non-selective NSAIDs and similar to the COX-2 inhibitors.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRINALGIN Approved UseUnknown |
|||
Primary | PRINALGIN Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4281380 |
Primary | PRINALGIN Approved UseUnknown |
||
Primary | PRINALGIN Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. | 1975 |
|
Skin sensitizing properties of arylalcanoic acids and their analogues. | 1979 Sep |
|
Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. | 2006 Oct 18 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/26888
The recommended dose is 200 mg daily, taken as two separate 100 mg doses, one tablet in the morning and one in the evening
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6141199
Alclofenac showed no mutagenic, transforming or clastogenic potential in any in vitro experiment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:52:22 GMT 2023
by
admin
on
Sat Dec 16 17:52:22 GMT 2023
|
Record UNII |
M9CP5H21N8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AB06
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
||
|
WHO-ATC |
M01AB06
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
31183
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
30951
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
m1004
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
107
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
C174701
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
100000087734
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
2826
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
244-795-4
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
DTXSID4020038
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL94081
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
DB13167
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
M9CP5H21N8
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
22131-79-9
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
SUB05299MIG
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY | |||
|
ALCLOFENAC
Created by
admin on Sat Dec 16 17:52:22 GMT 2023 , Edited by admin on Sat Dec 16 17:52:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |